Focus on current trends in the treatment of helicobacter pylori infection: An update

International Journal of Pharmaceutical Sciences Review and Research

Volumn 9, Issue 1, 2011, Pages 42-51

  Prasanthi, C H ^a   Prasanthi, N L ^a   Manikiran, S S ^a   Rama Rao, N ^a  

^a CHALAPATHI INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Bismuth salts; Diagnostic tests; Gastric lymphoma; Gastrorententive systems; Herbal formulations; Lipobeads

Indexed keywords

ACETOHYDROXAMIC ACID; ALGINIC ACID; AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; BERBERINE; BICARBONATE; BISMUTH SALICYLATE; BISMUTH SALT; CALCID; CALCIUM CARBONATE; CALIDER; CLARITHROMYCIN; CURCUMA LONGA EXTRACT; ESSENTIAL OIL; FROMILID; GINGER EXTRACT; GLYCYRRHIZA EXTRACT; HERBACEOUS AGENT; HEXACYCLINE; HISTAMINE H2 RECEPTOR ANTAGONIST; KLABAX; LANSOPRAZOLE; MANNITOL; METRONIDAZOLE; OMEPRAZOLE; OXYTETRACYCLINE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; STOMACH SECRETION INHIBITOR; TERMINALIA CHEBULA EXTRACT; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TRICLOSAN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL GROWTH; COMBINATION CHEMOTHERAPY; CURCUMA LONGA; DIAGNOSTIC TEST; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; ENDOSCOPIC BIOPSY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FECES ANALYSIS; GASTROINTESTINAL INFECTION; GINGER; GLYCYRRHIZA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MEDICINAL PLANT; MORNING DOSAGE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; REVIEW; SALIVA ANALYSIS; SEROLOGY; SIDE EFFECT; STOMACH CANCER; STOMACH LYMPHOMA; TERMINALIA CHEBULA; THYME; TONGUE; UREA BREATH TEST;

EID: 79960584809     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Bashir Mohammed Tijjani FMCP, Ali Bala Umar M D, Peptic ulcer disease and Helicobacter pylori infection, The international general of gastroenterology,8 2009,1-7.
2. Dunn B E, Cohen H, Blaster M J, Helicobacter pylori, Clin microbial rev,10 1997,720-41.
3. Javier Torres, Guillermo Perez-Perez, Karen J. Goodman, A comprehensive review natural history of H pylori infection in children. Archives of Medical research, 31, 2000,431-469.
4. Waqar A Qureshi, David Y, Graham, Diagnosis and Management of Helicobacter pylori infection, Upper GI disorders, 5, 18-29.
5. The H pylori and stomach ulcer report, Empowering You with Knowledge and Solutions for good health. Edition no 12(CPA), Nov 2009.
6. Helicobacter pylori www.medicaltribune.net/put/default. html.
7. Konturek J W, Discovery by jaworski of helicobacter pylori and its pathogenetic role in peptic ulcer, gastritis and gastric cancer. Journal of physiology and pharmacology, 54,2003,23-41.
8. Snyder J D, Veldhuyzen Van Zanten S. Novel diagnostic test to detect Helicobacter pylori infection: pediatric perspective. Can J gasteroenterol, 13, 1999,585-589.
9. Veldhuyzen Van Zanten, Tytgat K M, Rashid FA, Bowmen BM, A prospective comparison of symptoms and five diagnosis tests in patients with Helicobacter pylori positive and negative dyspepsia, Eur J Gastroenterol Hepatol 3,1991,463-468.
10. Dravid a. Hompes, The truth about the H pylori treatment, a comparison of treatment options for H pylori, 2008, 1-18.
11. Akiko Shiotani MD, Zhannat Z, Nurgalieva, Yoshio Yamaoka, David Y, Helicoobacter Pylori. Advances in gastroenterology,4,2009,1136-1126.
12. Bardonnet P L, Faivre V, Pugh W J, Piffaretti J C, Falson F. Gastroretentive Dosage forms: Overview and special case of Helicobacter pylori. Journal of controlled Release, 111, 2006,1-18.
13. Shah S H, Patel J K, Patel N V., Stomach specific floating drug delivery system: a review Int.J. PharmTech Research, 1, 2009,623-672.
14. Praveen nasa, Sheefali mahant, Deepika Sharma, Floating systems: a novel approach towards gastroretentive drug delivery systems. international general of pharmacy and pharmaceutical sciences, 2, 2010, 1-7.
15. Rahul Sutar, Rajashree Masareddy and Roopesh K, Hydrodynamically balanced tablets of Clarithromycin: an approach to prolong and increase the local action by gastric retention. Research Journal of Pharmaceutical, Biological and Chemical Sciences,2010,284-298.
16. Dettmar P W, Lloyd-Jones J G. Method of treatment of Helicobacter pylori infections with Triclosan. US patent 5286492, Feb5, 1994.
17. Umamaheshwari R B, Jain S, Bhadra D, Jain N K, Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori. J. Pharm. Pharmacol, 55, 2003, 1607-1613.
18. Yanga Libo, Jamshid Eshraghib, Reza Fassihia, A new intragastric delivery system for treatment of Helicobacter Pylori associated gastric: Invitro evaluation. Journal of controlled release, 57, 1999, 215-222.
19. Nagahara N, Akiyama Y, Nakao M, Tada M, Kitano M, Ogawa Y, Mucoadhesive microspheres containing amoxicillin for clearance of Helicobacter pylori. Antimicrob. Agents Chemother, 42,1998, 2492-2494.
20. Liu Z, Lu W, Qian L, Zhang X, Zeng P, Pan J, In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. J. Control. Release,102,2005, 135-144.
21. Katayama H, Nishimura T, Ochi S, Tsuruta Y, Yamazaki Y, Shibata K, Yoshitomi H., Sustained release liquid preparation using sodium alginate for eradication of Helicobacter pyroli. Biol. Pharm. Bull,22, 1999, 55-60.
22. Hejazi R, Amiji M, Stomach-specific anti-H. Pylori therapy: II. Gastric residence studies of tetracycline-loaded chitosan microspheres in gerbils. Pharma. dev. technol.8, 2003,253-262.
23. Umamaheshwari R B, Jain P, Jain N K, Site specific drug delivery of acetohydroxamic acid for treatment of H. pylori. STP pharma science 13, 2003,41-48.
24. Lingwood C, Huesca M, Kuksis A, The glycerolipid receptor for Helicobacter pylorus (and exoenzyme S) is phosphatidylethanolamine, Infect. immun,60,1992, 2470-2474.
25. Huesca M, Borgia S, Hoffman P, Lingwood C A, Acidic pH changes receptor binding specificity of Helicobacter pylori: a binary adhesion model in which surface heat shock (stress) proteins mediate sulfatide recognition in gastric colonization, Immun 64, 1996,2643-2648.
26. Umamaheshwari R B, Jain N K, Receptor-mediated targeting of lipobeads bearing acetohydroxamic acid for eradication of Helicobacter pylori. J. control. Release, 99,2004,27-48.
27. Malekzadeh F, Ehsanifar H, Shahamat M, Levin M, Colwell R R. Antibacterial activity of black myrobalan (Terminalia chebula Retz) against Helicobacter pylori. Int J Antimicrob Agents, 18, 2001,85-88.
28. Mahady G B, Pendland S L, Yun G S, Lu Z Z, Stoia A. Ginger (Zingiber officinale Roscoe) and the gingerols inhibit the growth of CagA+ strains of Helicobacter pylori. Anticancer Res, 23, 2003, 3699-3702.
29. Nostro A, Cellini L, Di Bartolomeo S, Di Campli E, Grande R, Cannatelli MA, Marzio L, Alonzo V. Antibacterial effect of plant extracts against Helicobacter pylori. Phytother Res, 19, 2005, 198-202.
30. Foryst-Ludwig A, Neumann M, Schneider-Brachert W, Naumann M. Curcumin blocks NF-kappa B and the motogenic response in Helicobacter pylori-infected epithelial cells. Biochem Biophys Res Commun,316, 2004,1065-1072.
31. Smith-Palmer A, Stewart J, Fyfe L. Antimicrobial properties of plant essential oils and essences against five important food-borne pathogens. Lett Appl Microbiol,26,1998, 118-122.
32. Krausse R, Bielenberg J, Blaschek W, Ullmann U, In vitro anti-Helicobacter pylori activity of Extractum liquiritiae, glycyrrhizin and its metabolites. J Antimicrob Chemother,54,2004,243-246.
33. Mahady G B, Pendland S L, Stoia A, Chadwick L R, In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis Canadensis. Phytother Res,17,2003,217-221.
34. Eveliina Myllyluoma, The role of probiotics in Helicobacter pylori infection. Foundation for Nutrition Research Helsinki 2007,1-86.
35. Giacomo Pagliaro, Maurizio Battino, The use of probiotics in gastrointestinal diseases. Canada Journal Gastroenterol, 15,2001,817-22.